•
FD
FDMT
4D Molecular Therapeutics, Inc. Common Stock
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
435.37M
Volume
460.43K
52W High
$12.34
52W Low
$2.24
Open
$7.62
Prev Close
$7.62
Day Range
7.52 - 7.79
About 4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Latest News
4DMT Appoints Kristian Humer as Chief Financial Officer
GlobeNewswire Inc.•Nov 17
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
GlobeNewswire Inc.•Oct 31
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
GlobeNewswire Inc.•Sep 11
4dMT Revenue Jumps 200 Percent in Q2
The Motley Fool•Aug 11
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
GlobeNewswire Inc.•Aug 11
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
GlobeNewswire Inc.•Jul 24
Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide
GlobeNewswire Inc.•May 7
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
GlobeNewswire Inc.•Mar 4